Sami Znati

Mr. Sami Znati


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SZSami Znati
Sami Znati
RCRebecca Carter
Rebecca Carter
MVMarcos Vasquez
Marcos Vasquez
AWAdam Westhorpe
Adam Westhorpe
HSHassan Shahbakhti
Hassan Shahbakhti
Ricky SharmaRicky Sharma
Ricky Sharma
Hepatocellular Carcinoma (HCC) is increasing in incidence worldwide and requires new approaches to therapy. The combination of anti-angiogenic drug therapy and radiotherapy is one promising new approach. The anti-angiogenic drug vandetanib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and RET proto-oncogene with radio-enhancement potential. To explore the benefit of combined vandetanib and radiotherapy treatment for HCC, we studied outcomes following combined treatment in pre-clinical models. Methods: Vandetanib and radiation treatment were combined in HCC cell lines grown in vitro and in vivo. In addition to 2D migration and clonogenic assays, the combination was studied in 3D spheroids and a syngeneic mouse model of HCC. Results: Vandetanib IC 50 s were measured in 20 cell lines and the drug was found to significantly enhance radiation cell kill and to inhibit both cell migration and invasion in vitro. In vivo, combination therapy significantly reduced cancer growth and improved overall survival, an effect that persisted for the duration of vandetanib treatment. Conclusion: In 2D and 3D studies in vitro and in a syngeneic model in vivo, the combination of vandetanib plus radiotherapy was more efficacious than either treatment alone. This new combination therapy for HCC merits evaluation in clinical trials.

16 November 2021 in British Journal of Radiology
Verified
Journal Article
Open access
LBLaura Beaton
Laura Beaton
MDMairead Daly
Mairead Daly
HTHenry Fj Tregidgo
Henry Fj Tregidgo
HGHelen Grimes
Helen Grimes
SMSyed Moinuddin
Syed Moinuddin
Ricky SharmaRicky Sharma
Ricky Sharma
Objective: To determine the feasibility of using radiopaque (RO) beads as direct tumour surrogates for image-guided radiotherapy (IGRT) in patients with liver tumours after transarterial chemoembolisation (TACE). Methods: A novel vandetanib-eluting RO bead was delivered via TACE as part of a first-in-human clinical trial in patients with either hepatocellular carcinoma or liver metastases from colorectal cancer. Following TACE, patients underwent simulated radiotherapy imaging with four-dimensional computed tomography (4D-CT) and cone-beam CT (CBCT) imaging. RO beads were contoured using automated thresholding, and feasibility of matching between the simulated radiotherapy planning dataset (AVE-IP image from 4D data) and CBCT scans assessed. Additional kV, MV, helical CT and CBCT images of RO beads were obtained using an in-house phantom. Stability of RO bead position was assessed by comparing 4D-CT imaging to CT scans taken 6–20 days following TACE. Results: Eight patients were treated and 4D-CT and CBCT images acquired. RO beads were visible on 4D-CT and CBCT images in all cases and matching successfully performed. Differences in centre of mass of RO beads between CBCT and simulated radiotherapy planning scans (AVE-IP dataset) were 2.0 mm mediolaterally, 1.7 mm anteroposteriorally and 3.5 mm craniocaudally. RO beads in the phantom were visible on all imaging modalities assessed. RO bead position remained stable up to 29 days post TACE. Conclusion: RO beads are visible on IGRT imaging modalities, showing minimal artefact. They can be used for on-set matching with CBCT and remain stable over time. Advances in knowledge: The role of RO beads as fiducial markers for stereotactic liver radiotherapy is feasible and warrants further exploration as a combination therapy approach.

5 May 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
LBLaura Beaton
Laura Beaton
HTHenry F.J. Tregidgo
Henry F.J. Tregidgo
SZSami Znati
Sami Znati
SFSharon Forsyth
Sharon Forsyth
NCNicholas Counsell
Nicholas Counsell
Ricky SharmaRicky Sharma
Ricky Sharma
To assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies. The VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7-21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging. Eight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441-404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%-100%). There were no significant changes in perfusion imaging parameters after TACE. BTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies.

14 January 2026 in Journal of Electronic Materials
Verified
Journal Article
Open access
PDF file
SZSami Znati
Sami Znati
SJSteven Johnston
Steven Johnston
MKMitra Keshavarz
Mitra Keshavarz
PMParsian K. Mohseni
Parsian K. Mohseni
Integration of electronic and optoelectronic devices via micro-transfer printing (µTP) enables efficient use of growth substrates by maximizing source wafer use, expanding the integrated device heterogeneity on a target over standard homogeneous flip-chip processes. The fabrication of device structures or “coupons” for µTP is associated with additional process complexity, however, and conventionally requires reactive-ion etching (RIE) for lateral isolation of coupons from the source wafer. As an alternative, metal-assisted chemical etching (MacEtch) is a simple, solution-based, and room-temperature catalytic etching method that employs a metallic catalyst to locally and anisotropically accelerate the vertical wet-etch rate of semiconductors. In this work, we used a MacEtch process to define, etch, and release Si µTP coupons using a one-step fabrication approach prior to heterogeneous integration with various print targets. Polysilicon-on-silicon oxide wafers were grown and used as a comparison to process standard, monocrystalline silicon-on-insulator (SOI) wafers for this study. The poly- and single-crystal SOI samples were patterned and catalytically etched to define the planar coupon dimensions, expose the buried oxide (BOX) layers, and laterally etch them to release the coupons in a single, benchtop processing step. The Au catalyst thickness, oxidant concentration, and release layer thickness were varied to evaluate their influence on the process. Using this approach, successful coupon fabrication by MacEtch and subsequent µTP of both poly-Si-on-SiO x and SOI were realized. It was determined that 90 nm Au film thickness and MacEtch solution of 12.5 M HF and 1.1 M H 2 O 2 were optimal etch conditions. This one-step approach to heterogeneous integration is energy-efficient and will streamline µTP by reducing process complexity from six process steps to three, alleviating equipment requirements and decreasing total fabrication time.

21 March 2019 in JMIR Preprints
Verified
Preprint
Open access
LBLaura Beaton
Laura Beaton
HTHenry F J Tregidgo
Henry F J Tregidgo
SZSami Znati
Sami Znati
SFSharon Forsyth
Sharon Forsyth
MCMatthew J Clarkson
Matthew J Clarkson
Ricky SharmaRicky Sharma
Ricky Sharma
BACKGROUND Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and is also a treatment option for patients with liver metastases from colorectal cancer. However, TACE is not a curative treatment, and tumor progression occurs in more than half of the patients treated. Despite advances and technical refinements of TACE, including the introduction of drug-eluting beads-TACE, the clinical efficacy of TACE has not been optimized, and improved arterial therapies are required. OBJECTIVE The primary objectives of the VEROnA study are to evaluate the safety and tolerability of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with resectable liver malignancies and to determine concentrations of vandetanib and the N-desmethyl metabolite in plasma and resected liver following treatment with BTG-002814. METHODS The VEROnA study is a first-in-human, open-label, single-arm, phase 0, window-of-opportunity study of BTG-002814 (containing 100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery in patients with resectable liver malignancies. Eligible patients have a diagnosis of colorectal liver metastases, or HCC (Childs Pugh A), diagnosed histologically or radiologically, and are candidates for liver surgery. All patients are followed up for 28 days following surgery. Secondary objectives of this study are to evaluate the anatomical distribution of BTG-002814 on noncontrast-enhanced imaging, to evaluate histopathological features in the surgical specimen, and to assess changes in blood flow on dynamic contrast-enhanced magnetic resonance imaging following treatment with BTG-002814. Exploratory objectives of this study are to study blood biomarkers with the potential to identify patients likely to respond to treatment and to correlate the distribution of BTG-002814 on imaging with pathology by 3-dimensional modeling. RESULTS Enrollment for the study was completed in February 2019. Results of a planned interim analysis were reviewed by a safety committee after the first 3 patients completed follow-up. The recommendation of the committee was to continue the study without any changes to the dose or trial design, as there were no significant unexpected toxicities related to BTG-002814. CONCLUSIONS The VEROnA study is studying the feasibility of administering BTG-002814 to optimize the use of this novel technology as liver-directed therapy for patients with primary and secondary liver cancer. CLINICALTRIAL ClinicalTrial.gov NCT03291379; https://clinicaltrials.gov/ct2/show/NCT03291379 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/13696